News & Insights
Lack of Diversity in Clinical Trials: Insights from a Two-Decade Analysis
Clinical trials are crucial in advancing medical knowledge and developing effective disease treatments. However, the underrepresentation of minority racial and ethnic groups in these trials has long been challenging. Despite efforts to address this issue, racial disparities persist, perpetuating a biased framework of medical evidence and innovation. The COVID-19 vaccine...
Reducing Cardiovascular Disease Disparities: The Role of Alirocumab
Cardiovascular disease (CVD) is a leading cause of mortality worldwide, affecting millions of people from diverse racial and ethnic backgrounds. However, recent research has shed light on significant disparities in CVD risk profiles among different populations. For instance, African-American/Black (AA/B) individuals have been found to face a higher risk of...
Empowering Precision Medicine: Genomic Data Analysis with Generative AI
Precision medicine, an innovative approach to healthcare, aims to tailor medical treatments to individual patients based on their unique genetic makeup. The advent of generative artificial intelligence (AI) has revolutionized the field of genomic data analysis, enabling researchers to extract valuable insights from vast amounts of genetic information. By harnessing...
Tailoring Therapies: Precision Medicine and Underserved Patient Groups
As we live and breathe patient-centricity in today's life science innovation lifecycle, we're reminded that the promise of precision medicine begins with the fundamental and foundational attributes of how we incorporate effective and impactful patient-centric design through multi-modal and multi-use disciplines. This article is a representation, out of a series...
Rubix LS Joins CancerX As A Founding Member
On Friday, June 2, 2023, at ASCO, CancerX – a public-private partnership co-hosted by Moffitt Cancer Center and the Digital Medicine Society (DiMe), alongside the Office for the National Coordinator for Health Information Technology (ONC) and Office of the Assistant Secretary for Health (OASH) – announced its founding members: 1104Health...
Pioneering Partnership to Revolutionize Clinical Trials: 360Medlink and Rubix LS Join Forces
LAWRENCE, MA, USA; MONTREAL, QC, CANADA & PARIS, FRANCE May 31, 2023/EINPresswire.com/ -- 360Medlink, a trailblazer in digital health platforms, and Rubix LS, a pioneer in clinical trial data intelligence and research, today announced a powerful partnership that promises to reshape the landscape of clinical trials. The collaboration aims to...
Advancing Diversity In Clinical Development
An update on progress and results The call for achieving representative diversity in clinical trials and development programs is not new — and indeed dates back more than five decades in the United States — but has been amplified over the course of the COVID-19 pandemic as the realities of...
Clinical Trial ‘Next Generation’ Workforce Fuels Diversity Optimism
When Reginald Swift, founder, and CEO at Rubix Life Sciences, looks into the clinical trial crystal ball, he’s excited by how new technologies will help advance patient diversity. Still, he’s even more encouraged by the next generation of up-and-coming professionals. “I'm grateful for the younger generation because they're socially aware,”...
[Podcast] How health outcomes can be realized through patient product and service innovation
Our Founder & CEO, Reginald Swift, had the chance to sit in on the Life Science Success podcast with Donald David to discuss the mission of Rubix LS and what it means to achieve equitable health outcomes. The live discussion can be found here https://www.lifesciencesuccess.com/ReginaldSwift/ as well as the video...
Rubix CEO Shares Personal Passion for Promoting Patient Diversity in Clinical Trials
It’s the memory of his late father and the hard battle against terminal lymphoma that fuels Reggie Swift’s passion for promoting greater diversity in clinical trials and health care. “My personal motivation is my father was diagnosed with stage 4 lymphoma, and he eventually passed away,” Swift, PhD, Founder/CEO, Rubix...
Rubix LS Nominated for Prestigious DEI Award
Rubix LS is among an illustrious group of finalists for an award in the Diversity and Inclusion (DI) Champions category from the BWB Awards, recognizing excellence and leadership in the healthcare industry, the company announced last week. As part of Biotech Week Boston, the award ceremony highlights innovative achievements from...
Had Covid-19 Ushered in the Era of Telemedicine?
Suppose the Covid-19 pandemic possessed any kind of silver lining. In that case, it could be that telehealth and many related tools and technologies appear to have passed the performance audition under stressful conditions, notes a white paper from Rubix, “Hospitals Adapting to Health Techniques for Patient Monitoring for Disease...
Care Disparities Put Minority Populations at Risk of Significant Neurodegenerative Threats
A cruel irony exists in the healthcare ecosystem of the United States: Proliferative Neurodegenerative conditions may occur more often in black, indigenous, and people of color patient populations even as they are underdiagnosed by well-meaning but ill-equipped healthcare professionals, says a new report from Rubix, “Understanding Neurodegenerative Cases and how...
Minority Populations Often Deprived of Innovative Treatments
Exciting medical and health innovations generated by clinical trials that could alleviate suffering and prolong life are often not reaching communities of color compared to non-minority communities, even though many chronic diseases are highly prevalent in these communities, according to a report from Rubix Life Sciences. “Minority populations could significantly...
Why Do African Americans and Other Minorities Have a Shorter Life Expectancy Than Whites?
Dangerous and troublingly stubborn health disparities persist among large population groups in the United States, according to a report from Rubix Life Sciences And there’s no “silver bullet” single solution to solving the problem. “Disparities are often the result of complex interactions among multiple factors, including unique populations and behavioral...
Rubix CEO Calls for Proactive Approach to Advancing Environmental Justice
By Reginald Swift, founder/CEO, Rubix LS Looking from space, our Earth appears exquisitely small and fragile. While we might have a different perspective about its size as we move about the planet’s land, oceans, and rivers during our day-to-day lives, it’s hard to argue with the idea that our environment...
Rubix CEO Outlines Vision for Greater Clinical Trial Patient Diversity
"We want to make sure that we put data into action to diversify the clinical trial patient population,” Reginald Swift, founder and CEO, Rubix LS told attendees of a panel at ATA2022 in Boston in early May 2022. “As we look to expand telehealth’s role in clinical trials, we...
It’s Time to Educate Minority Populations About the Benefits of Clinical Trials
By Reginald Swift, founder/CEO, Rubix LS Fresh off attending the ASCO 2022 conference, I was heartened to hear how much attention was focused on promoting minority participation in clinical trials. We all know it is the right thing to do morally, but it is also clear that diverse populations generate...
Rubix LS Applauds FDA Draft Guidance Calling for Enhanced Clinical Trial Diversity
“The moral, scientific, and business cases for promoting diversity in clinical trials have never been clearer,” says Reginald Swift, Ph. D, founder/CEO at Rubix Life Sciences. “It’s time to truly promote clinical trial diversity by harnessing data and working with experts who understand cultural nuances, especially for traditionally underserved patient...
Rubix LS Announces Milestone Achievement of 750k underserved patient data
Today we're excited to announce our progress towards targeting and serving 1M underrepresented participants through data by achieving 750,000 patients data supported. As the industry continues to dialogue around and about clinical research, clinical trials, and health equity, we must not forget the work that must continue to achieve equitable...
FDA & Clinical Trial Diversity - White Paper
As the life science industry faces even tougher challenges to ensure that patient diversity becomes a center focus for bringing new therapeutics to the market, look at how industry and collaborative partners should concentrate their efforts. Download the latest white paper below. FDA-Clinical-Trial-DiversityDownload
Reginald Swift of Rubix LS Named BBJ Power 50 Movement Maker
Swift along with the other honorees, was recognized for leadership in creating change and taking actionable steps for equity, inclusion, and diverse points of view. Reginald Swift is an innovator and a game-changer who started his biotech company in 2016 with only $600 dollars. With a career that started in...
What Health Informatics Should Be
Health informatics is an interdisciplinary field that uses information technology to organize and analyze health data and knowledge to improve health outcomes.1 Health informatics utilizes resources, devices, and digital methods to acquire, store, retrieve, and use personal health data. A common example is the electronic health record (EHR) that is accessible...
Rubix LS in the Boston Business Journal
After over a year of helping pharmaceutical companies reach underrepresented patients through its data analytics platform, Lawrence startup Rubix Life Sciences is getting into therapeutics itself. This summer, Rubix announced a new therapeutics division with plans to focus on neurodegenerative and infectious diseases. Now, it's building out a 40,000-square-foot clinical...
Rubix LS of Lawrence Unveils Plan for Clinical Trial Site 300 jobs -40,000 sq ft total Serving The Underrepresented
Local Clinical Research Facility in Lawrence, MassachusettsUnveils Plans to Build Clinical Trial Site for Under-represented Communities Rubix LS unveils a plan for a 40,000 sq. ft site centrally located in Lawrence, Mass.to focus on clinical therapeutic research needs of the under-represented August 16, 2021 (Washington, DC/Lawrence, MA) Rubix LS, a...
The Language Barrier: Ethnicity and Medicine
In medicine, we're looking at how specificity of language impacts patient behaviors for clinical recommendations. "This is the start of a series of articles we're posting on how dismantling barriers of patient engagement can lead to better outcomes. We're starting our series by discussing communication and language elasticity." The purpose...
Therapeutic Outcomes
Health disparities exist among specific population groups in the United States (US) to attain the highest health potential observed by differences in incidence, prevalence, mortality, the burden of disease, and other adverse healthindicators. It is a well-accepted idea that everyone should have a fair and equal opportunity to attain their...
[WHITE PAPER] Clinical Disparities in Disease Diagnosis
Exploring the relationships between clinical disparities in disease diagnosis and patient care and how we build to overcomes these challenges. Rubix LS - Clinical-Disparities-in-Disease-Diagnosis-and-Patient-CareDownload
Rubix LS Launches Therapeutics Division
We're 5 years old! What we've done to date and what we're going to do next.
Rubix LS Closes Seed Round for $1.25M
Funding Campaign Halfway to Goal for StarSense
November 7, 2020, Lawrence, MA - Rubix LS has announced today that it is nearly halfway towards it funding goal of $1M, at $450,000, for its lead platform, StarSense, a virtual clinical trial platform that has been piloted in the utility of patient testing for the infectious diseases under a...
CEO & Founder, Reginald Swift, on Shrimp Tank Podcast.
https://www.youtube.com/watch?v=Ua66XGAVD6M&feature=youtu.be
Rubix LS on Pharma Tech Outlook
Recently our Founder and CEO, Reginald Swift, sat down with the team at Pharma Tech Outlook magazine to discuss the changes happening with the pharma industry and how digital health, particularly virtual clinical trials are mobilizing access of pipeline therapeutics to the world for various disease states. An article to...
Health Data in the COVID-19 Crisis: How racial equity is widening for patients to gain access to treatment.
The coronavirus pandemic has placed extraordinary demands on the healthcare industry and the groups that are interconnected with the healthcare industry. The strain on obtaining adequate resources to establish a baseline of trending symptomatic patients and severity levels is spreading across the country. While many patients who may be exposed...
What we're doing for the COVID-19 crisis...
In the wake of the current COVID-19 crisis plaguing the world, many life science and health technology organizations are mobilizing ways to assist in containing and managing patient symptoms as well as racing toward a vaccine. While the world is approximately 12-18 months away from stemming the tide in the...
Rubix LS Is Supporting The Federal COVID-19 Response.
Rubix LS has joined the federal consortium of industry partners to fully develop plans and strategies for mobilizing robust response measures toward the growing COVID-19 worldwide pandemic in the United States. Rubix LS is joined by countless other firms, within the U.S, to fight against the emerging infectious pathogen that...
Massachusetts Life Science Company Target’s Coronavirus Detection
Rubix LS Successfully Isolated Protein Binding Receptors Previously in Ebola and Leishmaniasis, by Providing Real-Time Rapid Spectral Analysis of Key Proteins, is Actively Adapting Its Technology to Target Coronavirus WASHINGTON - Feb. 2, 2020 - Rubix LS engineered and deployed rapid diagnostic and elemental detection tools while actively working on studies of Ebola...
Rubix LS Expands with Asset Acquisition of Clinbotics
FOR IMMEDIATE RELEASE Rubix LS Continues 360 Degree Digital Health Campaign To Diversify Health Outcomes A respected leader in the life science and biotech product development and research sectors, Rubix LS has significantly boosted its growing digital healthcare campaign through its recent purchase of the assets of a virtual clinical...
An Interview: Digital Life Sciences & Inclusive Patient Outcomes from the CEO
Recently, the CEO had an opportunity to share his insights with Devin Thorpe, founder of Your Mark on The World, a non-profit group in which the sole mission is: "is to solve the world's biggest problems before 2045 by identifying and championing the work of experts who have created credible plans and...
Rubix LS enters into an agreement to support infectious disease data research
July 17, 2019 - Lawrence, MA - Today, Rubix LS is announcing that they're expanding their virtual clinical trial and disease intelligence platform that will include the nations: Morocco, Kenya, Indonesia and Brazil as part of a wider United Nations, www.un.org, health program for understanding commonalities of disease trends and...
Rubix LS is now an SBA 8a company
[et_pb_section admin_label="section"] [et_pb_row admin_label="row"] [et_pb_column type="4_4"][et_pb_text admin_label="Text"] July 16, 2019, Lawrence, MA - Today, Rubix LS is happy to announce that is reached SBA 8a status. Started in 1942, the SBA 8a program was developed to address vast disparities of economic opportunities, through business encouragement for minorities and key groups...
How IoT Technology is Transforming Healthcare
Technology has changed the way many manufacturers, industrial organizations and utilities operate. The addition of IoT to sensors has expanded their impact and use cases, delivering more connectivity and analytics to processes than ever before. As of today, these smart sensors are internet-enabled and are becoming more sophisticated than ever...
[Infographic] Can Digitalization Save Life on Earth?
As the world contends with new challenges with global warming, one of the threats humankind will be challenged with mitigating are ancient diseases. While 2 new diseases are identified every week, the scale of what we thought we were able to cure may not be as long-gone we once thought...
CRISPR - A genetic revolution or an enormous threat?
It outraged scientists across the globe. Media outlets were stunned. In November 2018, a scientist in China, He Jiankui, reported that he had created the world’s first human babies with CRISPR-edited genes: a pair of twin girls resistant to HIV. The director of the National Institutes of Health, Francis Collins,...
Diversity Alliance For Science Conference
Recently, the founder and CEO, Reginald Swift, had the opportunity to connect with the wider biotech community. As the nature of society is changing toward inclusion for diversity, the life science sector is creating initiatives to do the same for partnering with organizations. Below, Mr. Swift shares his thoughts from...
Rubix LS moves towards a new area of Life Science technology; Digital Life Sciences
February 27, 2019, Lawrence, MA- Life Science company Rubix LS growth has now expanded to encompass a new direction for the organization; Digital Life Sciences. As new tactics to deploy discovery towards patient-centric product development gains momentum, this new direction will refocus Rubix’s core offerings from its R&D expertise towards...
Minorities are under-represented in clinical trials
https://www.facebook.com/208747966176538/posts/766263487091647?sfns=st
Rubix LS Receives 2018 Best of Lawrence Award
Lawrence Award Program Honors the Achievement LAWRENCE, MA December 17, 2018 -- Rubix LS has been selected for 2018 Best of Lawrence Award in the Research and Product Development category by the Lawrence Award Program. Each year, the Lawrence Award Program identifies companies that we believe have achieved exceptional marketing...
Rubix LS announces new Phase II milestone data analysis in lead combination product candidate Project Hercules for targeting osteonecrotic (avascular necrosis) disease
Lawrence, MA - Today, Rubix LS announced the success of a critical milestone within the Phase IIa study of Project Hercules. Designed as an implantable combination device with wider applications toward targeting osteopenia, arthrodesis and certain malignancies such as onset osteonecrosis, the Phase IIa design study milestone was to incorporate dynamic...
Unpacking the reality of Bioterrorism in 2018
Anthrax. Ebola. Smallpox. These are just a few of the biological agents that could be weaponized for a bioterrorism attack and unlike a bombing or shooting, these microbial agents can incubate for days or weeks going unnoticed until unrelenting illnesses or deaths occur. Bioterrorism became an overwhelming concern after the...
Exploring the Challenges of Clinical Trial Failures
Creating a new drug is undoubtedly harrowing. The success rate of clinical trials is dependent on many factors such as patient enrollment, efficacy, bureaucracy, and awareness of the general public. These concerns are influential factors that ultimately affect which drugs are put on the market. The life sciences industry continues...
The impact of regulatory compliance on life sciences companies
On the quest to push the boundaries of innovation to develop and launch new products, companies have to address an increasing number of regulatory requirements which span multiple geographies, business activities and functions. While the life sciences industry has sustained growth and advances by drafting scalable compliance and business strategies...
Daisy Gallagher As New Senior Board Member of Rubix LS
October 31, 2018, Lawrence, MA - Rubix LS is announcing today veteran business executive and titan, Daisy Gallagher, promoted to the Board of Advisors. Gallagher is currently Chairman and Founder of Gallagher & Gallagher Worldwide, Inc., Chief Global Strategist, and Senior Executive Advisor, co-founder of SUSTAP LLC, and is an internationally known...
Yunche Wilson, named as new Chief Marketing Officer for Rubix LS
October 29, 2018, Lawrence, MA - Rubix LS is announcing today veteran marketing executive, Yunche Wilson has joined the company as Chief Marketing Officer. Wilson was most recently Marketing Manager and Director at Cyrus One, an Information Technology company, where she led the business through to an IPO. At Rubix LS,...
Life Sciences industry experiencing hiring challenges due to massive growth
[et_pb_section bb_built="1"][et_pb_row][et_pb_column type="4_4"][et_pb_text _builder_version="3.17.2"] Life sciences companies have always operated in a world of uncertainty. Issues around cost and pricing, clinical and operational innovation, customer and consumer engagement, and regulatory compliance have existed for decades. At the top of the list of challenges, building an organization of the future is...
Rubix LS Launches Data & Research Division
May 8, 2018, Lawrence, MA - Rubix LS is announcing today the launch of its new Data & Research division to its core business function. This is a step for Rubix LS to strongly position its expertise base to move as a technological think tank. With the addition of its new...
Rubix LS, recognized as recipient of ELSA award
Recognized as an Emerging Life Science Agent. Given to those who have demonstrated significant contribution to advancing unique science and engineering methodologies. April 12, 2018, Lawrence, MA - Rubix LS has been named a Top Innovation Winner in Futuristic Engineering as an Emerging Life Science Agent, honoring best-in-class learning and engineering...
Rubix LS Flies 4D from Prototyping to Now Manufacturing Scale
April 9, 2018, Lawrence, MA - Today Rubix LS announces achievement to scale up ability to achieve manufacturing consistency of 4D printed materials. It is a manufacturing process that will now incorporate the use of synthetic material intelligence; utilizing both software, fluid mesh, and moldable hardware components to make malleable devices....
Rubix LS is Introducing the I-pprentice Program
March 15, 2018, Lawrence, MA - Rubix LS is happy to announce today a new program in which will serve as a conduit for interested high school and early college students into a new apprenticeship program, aptly called I-pprentice. It is served to start within the late summer of 2018 and continue...
Rubix LS is Exploring Morocco
medical device firm, today announces that they will be working in tandem with the World Health Organization, to develop mechanisms that can transform some of the ecosystem's natural resources, within countries like Morocco, into disease treatment hubs. "The team here at Rubix LS is obviously excited to be apart of...